The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.
US-based cancer drug developer Gritstone Oncology has gone public in a $100m initial public offering in which biotech company Bluebird Bio bought $10m of shares.
The IPO involved Gritstone issuing almost 6.7 million shares priced at the top of the offering’s $13 to $15 range, giving it a market capitalisation of just over $430m. Its shares closed at $13.45 on their first day of trading on Friday, and at $15.05 yesterday.
Gritstone is working on immunotherapies that will…
